Kelly PN. The Cancer Immunotherapy Revolution. Science. 2018;359(6382):1344–5.

Article  CAS  PubMed  Google Scholar 

Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. Int Immunopharmacol. 2020;85:106628.

Article  CAS  PubMed  Google Scholar 

Yao L, Wang Q, Ma W. Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance. Cancers (Basel) 2023, 15(24).

Chen Q, Bao Y, Burner D, Kaushal S, Zhang Y, Mendoza T, Bouvet M, Ozkan C, Minev B, Ma W. Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8(+) T cell immune responses. Drug Deliv Transl Res. 2019;9(6):1095–105.

Article  PubMed  Google Scholar 

Chen Q, Lu L, Ma W. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers (Basel) 2022, 14(23).

Chen Q, Guo X, Ma W. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncol Res. 2023;32(1):49–60.

Article  PubMed  PubMed Central  Google Scholar 

Li H, Song W, Li Z, Zhang M. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front Immunol. 2022;13:992232.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 2022;10(1):12.

Article  PubMed  PubMed Central  Google Scholar 

Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, Zhao B, Deng M, Wang W, Mi X, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024;10(1):40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, Harris C, Khericha M, Vo KH, Kim M et al. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy. J Exp Med 2024, 221(6).

Shao S, Miao H, Ma W. Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs. Front Immunol. 2023;14:1295684.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu S, Wang Q, Ma W. Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy. Cytokine Growth Factor Rev. 2024;76:12–21.

Article  CAS  PubMed  Google Scholar 

Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14.

Article  PubMed  PubMed Central  Google Scholar 

Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, Baradaran B. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882.

Article  PubMed  PubMed Central  Google Scholar 

Liu M, Liu J, Liang Z, Dai K, Gan J, Wang Q, Xu Y, Chen YH, Wan X. CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro. Cells 2022, 11(22).

Abdou Y, Dees EC, Mortimer JE, Pohlmann PR, Johnson ML, Maziarz RT, Specht JM, Yuan Y, Ueno NT, Angelos M, et al. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. J Clin Oncol. 2023;41(16suppl):TPS2666–2666.

Article  Google Scholar 

Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11(1):103.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, Han D, Hong W, Wei W, Tu J. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605.

Article  CAS  PubMed  Google Scholar 

Li SY, Guo YL, Tian JW, Zhang HJ, Li RF, Gong P, Yu ZL. Anti-tumor Strategies by harnessing the phagocytosis of macrophages. Cancers (Basel) 2023, 15(10).

Abdin SM, Paasch D, Morgan M, Lachmann N. CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies. J Immunother Cancer 2021, 9(8).

Na YR, Kim SW, Seok SH. A new era of macrophage-based cell therapy. Exp Mol Med. 2023;55(9):1945–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kciuk M, Yahya EB, Mohamed Ibrahim Mohamed M, Rashid S, Iqbal MO, Kontek R, Abdulsamad MA, Allaq AA. Recent advances in Molecular mechanisms of Cancer Immunotherapy. Cancers (Basel) 2023, 15(10).

Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, Li J, Yao H, Chen K. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12(10):11149–65.

Article  PubMed  PubMed Central  Google Scholar 

Paasch D, Meyer J, Stamopoulou A, Lenz D, Kuehle J, Kloos D, Buchegger T, Holzinger A, Falk CS, Kloth C et al. Ex vivo generation of CAR macrophages from hematopoietic stem and progenitor cells for Use in Cancer Therapy. Cells 2022, 11(6).

Xu S, Wang C, Yang L, Wu J, Li M, Xiao P, Xu Z, Xu Y, Wang K. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Front Immunol. 2023;14:1199631.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, Gogas H. Beyond CTLA-4 and PD-1 inhibition: Novel Immune Checkpoint molecules for Melanoma Treatment. Cancers (Basel) 2023, 15(10).

Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Yang S, Wang Y, Jia J, Fang Y, Yang Y, Yuan W, Hu J. Advances in Engineered macrophages: a New Frontier in Cancer Immunotherapy. Cell Death Dis. 2024;15(4):238.

Article  PubMed  PubMed Central  Google Scholar 

Harrasser M, Gohil SH, Lau H, Della Peruta M, Muczynski V, Patel D, Miranda E, Grigoriadis K, Grigoriadis A, Granger D, et al. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC. Breast Cancer Res. 2022;24(1):39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li N, Geng S, Dong Z, Jin Y, Ying H, Li H, Shi L. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23(1):117.

Article  PubMed  PubMed Central  Google Scholar 

Su S, Lei A, Wang X, Lu H, Wang S, Yang Y, Li N, Zhang Y, Zhang J. Induced CAR-Macrophages as a Novel Therapeutic Cell type for Cancer Immune Cell therapies. Cells 2022, 11(10).

Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen K, Liu ML, Wang JC, Fang S. CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar. Biomol Biomed. 2024;24(3):465–76.

Article  PubMed  PubMed Central  Google Scholar 

Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799–820.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sly LM, McKay DM. Macrophage immunotherapy: overcoming impediments to realize promise. Trends Immunol. 2022;43(12):959–68.

Article  CAS  PubMed  Google Scholar 

Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.